ClinicalTrials.gg
Active, not recruitingNCT05850091PROACT 2Updated Jun 12, 2026

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

A Phase 4 interventional study of Rosuvastatin and Colchicine in Coronary Artery Disease, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.

Planned enrollment
16th of 34
200 · median 175
Started
2023
the only one that year
Phase 4
22 of 34
none open now
Registered
31st of 34
by date

Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one is the 16th largest by planned enrollment, is the only one that started in 2023, is one of 22 in phase 4, and was the 31st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing rosuvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

The goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-dose colchicine, and their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.

Read the detailed description

The main question PROACT 2 aims to answer is whether and how single or dual targeting of cholesterol-lowering and inflammation modulates coronary plaque in individuals with high polygenic risk and subclinical coronary atherosclerosis.

This is a double-blind randomized controlled trial of 200 individuals with high polygenic risk for coronary artery disease and subclinical plaque on coronary computed tomography angiography. Participants will be randomized into four equal treatment groups: group A receiving a placebo daily, group B receiving rosuvastatin 20mg daily, group C receiving colchicine 0.6mg daily, and group D receiving both rosuvastatin 20mg daily and colchicine 0.6mg daily. The primary outcome is change in total non-calcified plaque volume on coronary computed tomography angiography from baseline to one year. Multiple secondary plaque imaging and biomarker outcomes will be explored in this pilot mechanistic trial.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Polygenic risk
  • Atherosclerosis
  • Genetics
  • Genomic medicine
  • Polygenic score
  • Precision medicine
  • Preventive cardiology
  • Coronary plaque
  • Inflammation
  • Cholesterol
  • Lipids
  • Colchicine
  • Statin
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 40 and 75 years of age capable and willing to provide
  • Participant has high CAD PRS as defined on a clinical test
  • Participant with subclinical atherosclerosis defined as plaque visible on CCTA and causing \<70% luminal stenosis

Exclusion criteria

Exclusion Criteria:

  • Participant with a history of cardiovascular disease, defined by a diagnosis of coronary artery disease, peripheral artery disease, or cerebrovascular disease
  • Participant with a history of Liver disease (cirrhosis, active hepatitis, or severe hepatic disease) or any of the following recent lab results and determined to be non-transient: greater than 3 times the or total greater than 2 times the upper limit of normal (unless due to Gilbert syndrome)
  • Participant with estimated \<60 mL/min/1.73 m2 or creatinine greater than 2 times the upper limit of normal
  • Patient with history of an allergic reaction or significant sensitivity to iodinated contrast, colchicine, or statins
  • Patient currently taking LDL cholesterol lowering or anti- inflammatory medications including colchicine
  • Participants requiring regular drugs known to be potent CY2P inhibitors (eg. ketoconazole, clarithromycin)
  • Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study
  • Participant with ≥ 40 kg/m2
  • Participant unable to provide
  • Participant unable to hold breath for 10 seconds
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Placebo comparator
    Group A

    Participants will receive placebo daily

    Drug: Placebo

  • Active comparator
    Group B

    Participants will receive rosuvastatin 20mg daily and placebo daily

    Drug: Rosuvastatin · Drug: Placebo

  • Active comparator
    Group C

    Participants will receive colchicine 0.6mg daily and placebo daily

    Drug: Colchicine · Drug: Placebo

  • Active comparator
    Group D

    Participants will receive rosuvastatin 20mg daily and colchicine 0.6mg daily

    Drug: Rosuvastatin · Drug: Colchicine

Interventions

  • Pharmacotherapy for reduction in LDL cholesterol level

  • Pharmacotherapy for inflammation inhibition

  • DrugPlacebo

    Capsule with sugar pill that mimics active study drugs

06

What researchers measure

Primary outcomes

  1. Change in total non-calcified plaque volume from baseline to one year

    The primary outcome of this study is the change in total non-calcified plaque volume between the two groups from baseline to one year. This outcome will be measured using coronary computed tomography angiography (CCTA) and reported in cubic millimeters (mm³). The comparison of the changes in non-calcified plaque volume will help assess the effectiveness of the intervention on plaque progression and composition.

    Time frame: 1 year

Secondary outcomes

  1. Change in total plaque volumes from baseline to one year

    The change in the following plaque volumes will be compared between the two groups from baseline to one year: total plaque volume, total calcified plaque volume, and total low attenuation plaque volume. These volumes will be analyzed individually and reported in cubic millimeters (mm³).

    Time frame: 1 year

  2. Change in maximal luminal stenosis from baseline to one year

    The change in maximal luminal stenosis will be compared between the two groups from baseline to one year, reported as a percentage (%).

    Time frame: 1 year

  3. Change in calcium score from baseline to one year

    The change in calcium score will be compared between the two groups from baseline to one year, reported in Agatston units.

    Time frame: 1 year

  4. Change in number of high-risk features from baseline to one year

    The change in the number of high-risk features will be compared between the two groups from baseline to one year, reported as a count (number of features).

    Time frame: 1 year

  5. Change in fat attenuation index from baseline to one year

    The change in fat attenuation index will be compared between the two groups from baseline to one year, reported in Hounsfield units (HU).

    Time frame: 1 year

  6. Progression in non-calcified plaque volume from baseline to one year

    The proportion of participants who had progression in non-calcified plaque volume from baseline to one year (%)

    Time frame: 1 year

  7. Change in low-density lipoprotein cholesterol (LDL-C) from baseline to one year

    The change in low-density lipoprotein cholesterol (LDL-C) will be compared between the two groups from baseline to one year, reported in milligrams per deciliter (mg/dL).

    Time frame: 1 year

  8. Change in C-reactive protein (CRP) from baseline to one year

    The change in C-reactive protein (CRP) will be compared between the two groups from baseline to one year, reported in milligrams per liter (mg/L).

    Time frame: 1 year

  9. Change in Interleukin-6 and Interleukin-1 beta (IL-1ß) from baseline to one year

    The change in Interleukin-6 (IL-6) and Interleukin-1 beta (IL-1ß) will be compared between the two groups from baseline to one year. Both biomarkers will be analyzed individually and reported in picograms per milliliter (pg/mL).

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Abou-Karam R, Kim MS, Jemma Cho SM, Bitar F, Gady S, Cheng F, Thompson AG, Karlson EW, Natarajan P, Ellinor PT, Foldyna B, Ghebremichael MS, Atlas SJ, Ridker PM, Lu MT, Fahed AC. Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials. J Am Coll Cardiol. 2026 Feb 6:S0735-1097(25)10563-9. doi: 10.1016/j.jacc.2025.12.032. Online ahead of print. PubMed 41706060 ↗

Individual participant data

Plan to share: Yes — Data will be tabulated and analyzed. Study site will not share any of the subject identifiers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 41 months is above that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2023
First posted
May 9, 2023
StartActual
Dec 7, 2023
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05850091
Responsible party
Akl C. Fahed, MD, MPH (Interventional Cardiologist, Massachusetts General Hospital) — Principal investigator
First posted
May 9, 2023
Start date
Dec 7, 2023
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jun 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Colchicine

Start the discussion